1a. Personal details Full name Title First name Second name(s) Family name Dr. Khaled Fathi Hassan Greish Present position Associate Professor /Adjunct Associate Professor Organisation/Employer Arabian Gulf University/University of Utah-USA Contact Address Department of Molecular medicine/ Department of Pharmaceutical Chemistry Aljawhara Centre for molecular medicine

Work telephone 1723793 Mobile 34358697 Email [email protected] Personal website (if http://www.otago.ac.nz/phal/people/profile/index.html?id=1071 applicable) 1b. Academic qualifications Year Qualification Discipline University/institute 2006 Ph.D Targeted anticancer Graduate School of Medical Sciences, therapy Kumamoto University, Japan 1997 Master Clinical oncology Suez Canal University, Ismailia, 1992 MB.B.Ch Medicine and surgery Faculty of Medicine, Suez Canal with honor University, Ismailia, Egypt

1c. Professional positions held

Organisation Year Job title

2015- Associate professor level 7 Department of Molecular medicine, Arabian gulf university 2014- Adjunct Associate Professor Department of pharmaceutical sciences, University of Utah, and Nano institute of Utah 2014- Senior Lecture Department of Pharmacology and Toxicology, University of Otago, New Zealand July 2011- Lecturer Department of Pharmacology and Toxicology, University of Otago, New Zealand 2010-2011 Visiting Professor Utah-Inha DDS Center, South Korea 2009- Research assistant professor Department of pharmaceutical sciences, University of Utah, and Nano institute of Utah 2008-2009 Research associate Department of pharmaceutical sciences, University of Utah 2006-2008 JSPS post-doctoral Fellow Faculty of Pharmaceutical Sciences, Sojo University , Japan 1995-2001 Assistant lecturer Faculty of Medicine, Suez Canal University, Ismailia, Egypt

2011- lecturer Faculty of Medicine, Suez Canal University, Ismailia, Egypt

1d. Present research/professional speciality Nanomedicine, Anticancer drug delivery, and tumor vascular biology 1e. Total years research experience 23 (post- master) years 1f. Professional distinctions and memberships (including honours, prizes, scholarships, boards or governance roles, etc)  2019, Invited speaker: 2nd Pearl International Pediatric Conference, Bahrain  2019 Invited Speaker : The millennium biotechnology pan-Arab conference & bio- business forum" MBPAC, Bahrain  2019, Plenary speaker, 10th RAKMHSU Students Scientific Conference, UAE  2019 Invited Speaker, University De Catania,  2017, Invited speaker, 3th International Conference and Exhibition on Nanomedicine and Pharmaceutical Nanotechnology, , Italy: https://nanotechnology.pharmaceuticalconferences.com/speaker/2017/khaled-greish- arabian-gulf-university-bahrain  2017, Best presentation, University De Catania, Italy  2015,Invited Speaker, Kuwait University  2015, Session chair, Controlled Release Society: 40th annual meeting, UK.  2014, Chair of Seattleite meeting committee, Controlled release Society  2014, Early career award for distinction in research http://www.otago.ac.nz/news/news/otago073898.html  2014, 3rd International Conference on Drug Discovery and Development, Dubai, UAE: Best paper award  2014, invited speaker, French Society for Nanomedicine (SFNano), Porto, Portugal  2014, invited speaker, 3rd International Conference on Drug Discovery and Development, Dubai, UAE.  2013, invited speaker, Joint Australasian Pharmaceutical Science Association Conference, and New Zeeland Controlled Release Society meeting. Dunedin , New Zealand  2013, invited speaker, Nano- institute of Utah Seminar, Salt lake city, Utah.  2013, invited Speaker, National Centre for Natural Products Research, the University of Mississippi, Oxford USA.  2013, invited Speaker, 15th FDB Annual Conference, Dunedin, New Zealand.  2012, Invited speaker, Controlled Release Society: 37 annual meeting. Quebec, Canada.  2012, Session chair, Controlled Release Society: 37 annual meeting, Quebec, Canada.  2012, Invited speaker for the 12th European Symposium on Controlled Drug Delivery. Egmondaan Zee, The Netherlands  2010, Controlled Release Society: CRS membership of the inaugural College of Fellows.  2008, Invited Speaker, CRS webcast seminar  2008, CRS -Nagai post-doctoral achievement award.  2007, Invited Speaker, the 23rd Japan Drug Delivery System research society meeting, Kumamoto, Japan.  2007, Award of Young Scientists Refereeing Program (Biomaterials).  2006, Japanese Society for Promotion of Science (JSPS) post-doctoral Scholarship.  2001, Ministry of Education, Culture, Sports, Science and Technology, Government of Japan (MONBUSHO); Scholarship for studying Ph.D., Japan.  I am reviewer for; Biomaterials, ActaBiomaterialia, Journal of controlled release, Nanomedicine, Molecular pharmaceutics, The Journal of Gene Medicine, Journal of drug targeting, Drug Discovery today, Nanotechnology, Science and Applications, Nanomedicine, Medical Science Monitor.

Professional Affiliations/ Memberships (List)

 Satellite meeting committee, Controlled Release Society  Centre for Translational Cancer Research, Otago University  New Zealand local chapter of Controlled Release Society, committee member  Formulation and Delivery of Bioactives (FDB), steering committee member  Center for Bioengineering and Nanomedicine , Otago University  MARS Spectral Molecular Imaging group  Nano - institute of Utah  Controlled Release Society  Japanese Cancer Society  Japanese Drug Delivery System Society  Egyptian Medical Syndicate, 1991-present (a) Research Expertise  Developing and evaluating anticancer drug delivery systems to improve the efficacy and safety of approved and novel anticancer chemotherapeutics.  Selective targeting of chemotherapeutic drugs by conjugation of folic acid and glucose to nanodeliverymiceller system.  Development of oral Nan-delivery systems for oral delivery of targeted anticancer agents.  Use of low voltage alternate current to locally enhance drug delivery.  Evaluations of the unique tumor cell properties that favorers enhanced uptake of the novel drug delivery formulations.  Extending the use of delivery systems to other disease conditions such as chronic neuropathic pain.  Evaluation of the use of gold and silver nanoparticles for concomitant diagnostic and treatment application (theranostic applications).

1g. Total number of peer Journal Books, book Conference Patents reviewed publications and articles chapters, books proceedings patents edited 85 10 >150 3

These publications have received 6317 citations with an h index of 33 according to google scholars. https://scholar.google.co.nz/citations?user=gKwc5WYAAAAJ&hl=en

ORCI ID: https://orcid.org/0000-0002-0787-7070 Researcher ID: P-4938-2017

PART 2 2a. Research publications and dissemination Peer-reviewed journal articles 1. H. Alimoradi, Khaled Greish, Allan Gamble, Gregory Giles: Controlled Delivery of Nitric Oxide for Cancer Therapy, Pharmaceutical Nanotechnology, 7(4) 2019 . DOI: 10.2174/ 2211738507666190429111306. 2. V. Pittalà, L. Vanella, C.B. Maria Platania, L. Salerno, M. Raffaele, E. Amata, A. Marrazzo, G. Floresta, G. Romeo, K. Greish, Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents, Future medicinal chemistry 11(13) (2019) 1523-1536. 3. R. Mohammadpour, M.A. Dobrovolskaia, D.L. Cheney, K.F. Greish, H. Ghandehari, Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications, Advanced drug delivery reviews (2019). 4. M.A. Morsy, S. Gupta, A.B. Nair, K.N. Venugopala, K. Greish, M. El-Daly, Protective Effect of Spirulina platensis Extract against Dextran-Sulfate-Sodium-Induced Ulcerative Colitis in Rats, Nutrients 11(10) (2019) 2309. 5. H. Alimoradi, A. Barzegar-Fallah, I. Sammut, K. Greish, G. Giles, Encapsulation of tDodSNO generates a nitric oxide releasing nanoparticle, Free Radical Biology and Medicine 128 (2018) S117. 6. H. Alimoradi, A. Barzegar-Fallah, I.A. Sammut, K. Greish, G.I. Giles, Data characterizing the biophysical and nitric oxide release properties of the tDodSNO–Styrene maleic anhydride nanoparticle SMA-tDodSNO, Data in brief 21 (2018) 1771-1775. 7. H. Alimoradi, A. Barzegar-Fallah, I.A. Sammut, K. Greish, G.I. Giles, Encapsulation of tDodSNO generates a photoactivated nitric oxide releasing nanoparticle for localized control of vasodilation and vascular hyperpermeability, Free Radical Biology and Medicine 130 (2019) 297-305. 8. Alimoradi, K. Greish, A. Barzegar-Fallah, L. Alshaibani, V. Pittalà, Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity, International journal of nanomedicine 13 (2018) 7771. 9. F. Bahman, S. Elkaissi, K. Greish, S. Taurin, Polymeric Micelles in Management of Lung Cancer, Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer, Academic Press2019, pp. 193-216. 10. F. Bahman, K. Greish, S. Taurin, Nanotechnology in insulin delivery for management of diabetes, Pharmaceutical nanotechnology (2019). 11. K. Greish, Recent and future advances in anticancer drug delivery: an interview with Khaled Greish, Therapeutic delivery 9(6) (2018) 409-412. 12. K. Greish, A. Alqahtani, A. Alotaibi, A. Abdulla, A. Bukelly, F. Alsobyani, G. Alharbi, I. Alkiyumi, M. Aldawish, T. Alshahrani, The Effect of Silver Nanoparticles on Learning, Memory and Social Interaction in BALB/C Mice, International journal of environmental research and public health 16(1) (2019) 148. 13. K. Greish, M. Fateel, S. Abdelghany, N. Rachel, H. Alimoradi, M. Bakhiet, A. Alsaie, Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer, Journal of drug targeting 26(7) (2018) 610-615. 14. K. Greish, A. Jasim, N. Parayath, S. Abdelghany, A. Alkhateeb, S. Taurin, H. Nehoff, Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme, Journal of drug targeting 26(8) (2018) 692-708. 15. K. Greish, A. Mathur, R. Al Zahrani, S. Elkaissi, M. Al Jishi, O. Nazzal, S. Taha, V. Pittalà, S. Taurin, Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer, Journal of Controlled Release 291 (2018) 184-195. 16. K. Greish, A. Mathur, M. Bakhiet, S. Taurin, Nanomedicine: is it lost in translation?, Therapeutic delivery 9(4) (2018) 269-285. 17. K. Greish, H. Nehoff, F. Bahman, T. Pritchard, S. Taurin, Raloxifene nano-micelles effect on triple- negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor, Journal of drug targeting (2019) 1-14. 18. K. Greish, V. Pittalà, S. Taurin, S. Taha, F. Bahman, A. Mathur, A. Jasim, F. Mohammed, I. El-Deeb, S. Fredericks, Curcumin–Copper Complex Nanoparticles for the Management of Triple-Negative Breast Cancer, Nanomaterials 8(11) (2018) 884. 19. K. Greish, L. Salerno, R. Al Zahrani, E. Amata, M. Modica, G. Romeo, A. Marrazzo, O. Prezzavento, V. Sorrenti, A. Rescifina, Novel structural insight into inhibitors of heme oxygenase-1 (HO-1) by new imidazole-based compounds: Biochemical and in vitro anticancer activity evaluation, Molecules 23(5) (2018) 1209. 20. K. Greish, S. Taurin, M.A. Morsy, The effect of adjuvant therapy with TNF-α on animal model of triple-negative breast cancer, Therapeutic delivery 9(5) (2018) 333-342. 21. A. Jasim, S. Abdelghany, K. Greish, Current update on the role of enhanced permeability and retention effect in cancer nanomedicine, Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes, Academic Press2017, pp. 62-109. 22. Greish K, Fateel M, Abdelghany S et al. Sildenafil Citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer. Journal of drug targeting 1- 23 (2017). 23. Greish K, Jasim A, Parayath N et al. Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme. Journal of Drug Targeting , 1-46 (2017) 24. Greish K, Taha S, Jasim A et al. Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease. Clinical and translational medicine 6(1), 28 (2017). 25. Martey O, Nimick M, Taurin S, Sundararajan V, Greish K, Rosengren RJ. styrene maleic acid- encapsulated rl71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer. International journal of nanomedicine 12 7225 (2017) 26. Luong D, Kesharwani P, Deshmukh R, Amin MCIM, Gupta U, Greish K, AK Iyer. PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomaterialia 2016; 43:14-29. IF 6.008 27. Parayath NN, Nehoff H, Norton SE, Highton AJ, Taurin S, Kemp RA, Greish K. Styrene maleic acid-encapsulated paclitaxel micelles: antitumor activity and toxicity studies following oral administration in a murine orthotopic colon cancer model. International Journal of Nanomedicine 2016; 11: 3979-91. IF 4.320 28. Alimoradi H, Matikonda S S, Gamble A B, Giles G I, Greish K. Hypoxia Responsive Drug Delivery Systems in Tumor Therapy. Current Pharamceutical Design. 2016; 22(19): 2808-20. IF 1.54 29. Saisyo A, Nakamura H, Fang J, Tsukigawa K Tsukigawa, Greish K, Furukawa H, Maeda H. pH- sensitive polymeric cisplatin-ion complex with styrene-maleic acid copolymer exhibits tumor- selective drug delivery and antitumor activity as a result of the enhanced permeability and retention effect. Colloids and Surfaces B: Biointerfaces. 2016; 138: 128-137. IF 3.902 30. Archibald M, Pritchard T, Nehoff H, Rosengren RJ, Greish K, Taurin S. A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. International journal of nanomedicine. 2016; 11: 179. IF 4.320 31. Parayath NN, Nehoff H, Taurin S, Greish K . Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies. Current Pharmaceutical Biotechnology. 2016; 17(8): 683- 699. IF 2.51 32. Nehoff H, Parayath NN, Melanie McConell, Taurin S, Greish K .A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme. Oncotarget. 2015; 6(35): 37948. IF 6.6 33. Parayath NN, Nehoff H, Müller P, Taurin S, Greish K. styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery–dual uptake through enterocytes and M-cells. International journal of nanomedicine. 2015; 10:4653. IF 4.38 34. Daruwalla J, Greish K, Malcontenti-Wilson C, Muralidharan V, Maeda H, Christophi C. Styrene maleic acid copolymer–pirarubicin induces tumor-selective oxidative stress and decreases tumor hypoxia as possible treatment of colorectal cancer liver metastases. Surgery. 2015; 1:236-47. IF 3.38 35. Xian S, Parayath NN, Nehoff H, Giles NM, Greish K. The use of Styrene maleic acid nanomicelles encapsulating the synthetic cannabinoid analog WIN55, 212-2 for the treatment of cancer. Anticancer Research. 2015; 35:4707-12. IF 1.82 36. Pritchard T, Rosengren RJ, Greish K, Taurin S. Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer. Journal of Drug Targeting. 2015:1-9. IF 2.74 37. Tsukigawa K, Liao L, Nakamura H, Fang J, Greish K,Otagiri M, et al. Synthesis and therapeutic effect of styrene–maleic acid copolymer‐conjugated pirarubicin. Cancer science. 2015; 106:270-8. IF 3.52 38. Salerno L, Pittalà V, Romeo G, Modica MN, Marrazzo A, Siracusa MA Parayath NN, GreishK Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines. European Journal of Medicinal Chemistry(2015) 96: 162-172. IF 3.44 39. Linsell O, Brownjohn PW, Nehoff H, Greish K, Ashton JC. Effect of styrene maleic acid WIN55, 212-2 micelles on neuropathic pain in a rat model. Journal of drug targeting. 2014(0):1-7. 40. Mohamed S, Parayath NN, Taurin S, Greish K. Polymeric nano-micelles: versatile platform for targeted delivery in cancer. Therapeutic delivery. 2014;5(10):1101-21. 41. Taurin, S.; Nehoff, H.; Van Aswegen, T.; Rosengren, R. J.; Greish, K. A Novel Role for RaloxifeneNanomicelles in Management of Castrate Resistant Prostate Cancer. BioMed Research International(2014),2014, 14. 42. Nehoff, H., Parayath, N., Domanovitch, L., Taurin, S., Greish, K (2014). Nanomedicine for drug targeting: Strategies beyond the EPR effect. International Journal of Nanomedicine. (2014) ;9:2539- 55.IF 4.38 43. Nehoff H, Parayath N, Taurin S, Greish K. The Influence of Drug Loading on Caveolin-1 Mediated Intracellular Internalization of Doxorubicin Nanomicelles in vitro. J NanomedNanotechnol. 2014;5(197):2.. IF 4.68 44. S. Taurin, H. Nehoff, J. Diong, L. Larsen, R. Rosengren, K. Greish , Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer, J Drug Target, (2013) 21 (7), 675- 683. 45. Thiagarajan, G.; Sadekar, S.; Greish, K.; Ray, A.; Ghandehari, H., Evidence of Oral Translocation of Anionic G6. 5 Dendrimers in Mice. Molecular pharmaceutics 2013,10 (3), 988-998. 46. Thiagarajan, G.; Greish, K.; Ghandehari, H., Charge affects the oral toxicity of poly (amido amine) dendrimers. European Journal of Pharmaceutics and Biopharmaceutics 2013. 47. T. Yu, K. Greish, L.D. McGill, A. Ray, H. Ghandehari, Influence of Geometry, Porosity, and Surface Characteristics of Silica Nanoparticles on Acute Toxicity: Their Vasculature Effect and Tolerance Threshold, ACS Nano, 6 (2012) 2289-2301.IF 12.88 48. S. Taurin, H. Nehoff, K. Greish, Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?, Journal of controlled release : official journal of the Controlled Release Society, 164 (2012) 265-275. 49. R. Price, J. Gustafson, K. Greish, J. Cappello, L. McGill, H. Ghandehari, Comparison of silk- elastinlike protein polymer hydrogel and poloxamer in matrix-mediated gene delivery, Int J Pharm, 427 (2012) 97-104. 50. K. Greish, G. Thiagarajan, H. Herd, R. Price, H. Bauer, D. Hubbard, A. Burckle, S. Sadekar, T. Yu, A. Anwar, A. Ray, H. Ghandehari, Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles, Nanotoxicology, 6 (2012) 713-723. 51. K. Greish, G. Thiagarajan, H. Ghandehari, In vivo methods of nanotoxicology, Methods in molecular biology, 926 (2012) 235-253. 52. J. Fang, K. Greish, H.B. Qin, L. Liao, H. Nakamura, M. Takeya, H. Maeda, HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: In vitro and in vivo anticancer effect, European Journal of Pharmaceutics and Biopharmaceutics, 81 (2012) 540-547. 53. B. Yadav, K. Greish, Selective inhibition of hemeoxygenase-1 as a novel therapeutic target for anticancer treatment, J NanomedicNanotechnol S, 4 (2011). 54. A. Ray, N. Larson, D.B. Pike, M. Gruner, S. Naik, H. Bauer, A. Malugin, K. Greish, H. Ghandehari, Comparison of Active and Passive Targeting of Docetaxel for Prostate Cancer Therapy by HPMA Copolymer-RGDfK Conjugates, Molecular pharmaceutics, 8 (2011) 1090-1099. 55. N. Larson, K. Greish, H. Bauer, H. Maeda, H. Ghandehari, Synthesis and evaluation of poly(styrene- co-maleic acid) micellar nanocarriers for the delivery of tanespimycin, Int J Pharm, 420 (2011) 111- 117. 56. K. Greish, A. Ray, H. Bauer, N. Larson, A. Malugin, D. Pike, M. Haider, H. Ghandehari, Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy, Journal of Controlled Release, 151 (2011) 263-270. 57. Greish K, Muller K, IvanaJay J, Lee DH (2011) The Cooperative Anticancer Effect of Dual Styrenemaleic Acid Nano-Miceller System against Pancreatic Cancer. J NanomedicNanotechnol S4:004. doi:10.4172/2157-7439.S4-004 58. K. Greish, Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet?, Drug Discovery Today: Technologies, (2011). 59. A.J. Gormley, K. Greish, A. Ray, R. Robinson, J.A. Gustafson, H. Ghandehari, Gold nanorod mediated plasmonicphotothermal therapy: A tool to enhance macromolecular delivery, Int J Pharm, 415 (2011) 315-318. 60. J.A. Gustafson, R.A. Price, K. Greish, J. Cappello, H. Ghandehari, Silk-Elastin-like Hydrogel Improves the Safety of Adenovirus-Mediated Gene-Directed Enzyme-Prodrug Therapy, Molecular pharmaceutics, 7 (2010) 1050-1056. 61. K. Greish, J. Frandsen, S. Scharff, J. Gustafson, J. Cappello, D.Q. Li, B.W. O'Malley, H. Ghandehari, Silk-elastinlike protein polymers improve the efficacy of adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors, Journal of Gene Medicine, 12 (2010) 572-579. 62. J. Daruwalla, M. Nikfarjam, K. Greish, C. Malcontenti-Wilson, V. Muralidharan, C. Christophi, H. Maeda, In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: Survival improvement and inhibition of liver metastases, Cancer Sci, 101 (2010) 1866- 1874. 63. A. Nagamitsu, K. Greish, H. Maeda, Elevating Blood Pressure as a Strategy to Increase Tumor- targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors, Jpn J ClinOncol, 39 (2009) 756-766. 64. J. Gustafson, K. Greish, J. Frandsen, J. Cappello, H. Ghandehari, Silk-elastinlike recombinant polymers for gene therapy of head and neck cancer: From molecular definition to controlled gene expression, Journal of Controlled Release, 140 (2009) 256-261. 65. K. Greish, K. Araki, D.Q. Li, B.W. O'Malley, R. Dandu, J. Frandsen, J. Cappello, H. Ghandehari, Silk-Elastinlike Protein Polymer Hydrogels for Localized Adenoviral Gene Therapy of Head and Neck Tumors, Biomacromolecules, 10 (2009) 2183-2188. 66. J. Fang, A.K. Iyer, T. Seki, H. Nakamura, K. Greish, H. Maeda, SMA-copolymer conjugate of AHPP: A polymeric inhibitor of xanthine oxidase with potential antihypertensive effect, Journal of Controlled Release, 135 (2009) 211-217. 67. J. Daruwalla, K. Greish, C. Malcontenti-Wilson, V. Muralidharan, A. Iyer, H. Maeda, C. Christophi, Styrene Maleic Acid-Pirarubicin Disrupts Tumor Microcirculation and Enhances the Permeability of Colorectal Liver Metastases, J Vasc Res, 46 (2009) 218-228. 68. M. Mayerhofer, K.V. Gleixner, J. Mayerhofer, G. Hoermann, E. Jaeger, K.J. Aichberger, R.G. Ott, K. Greish, H. Nakamura, S. Derdak, P. Samorapoompichit, W.F. Pickl, V. Sexl, H. Esterbauer, I. Schwarzinger, C. Sillaber, H. Maeda, P. Valent, Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib, Blood, 111 (2008) 2200-2210. 69. E. Hadzijusufovic, L. Rebuzzi, K.V. Gleixner, V. Ferenc, B. Peter, R. Kondo, A. Gruze, M. Kneidinger, M.T. Krauth, M. Mayerhofer, P. Samorapoompichit, K. Greish, A.K. Lyer, W.F. Pickl, H. Maeda, M. Willmann, P. Valent, Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis, ExpHematol, 36 (2008) 1461-1470. 70. J. Fang, D. Deng, H. Nakamura, T. Akuta, H. Qin, A.K. Iyer, K. Greish, H. Maeda, Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated D-amino acid oxidase, International Journal of Cancer, 122 (2008) 1135-1144. 71. M. Regehly, K. Greish, F. Rancan, H. Maeda, F. Bohm, B. Roder, Water-soluble polymer conjugates of ZnPP for photodynamic tumor therapy, BioconjugChem, 18 (2007) 494-499. 72. R. Kondo, K.V. Gleixner, M. Mayerhofer, A. Vales, A. Gruze, P. Samorapoompichit, K. Greish, M.T. Krauth, K.J. Aichberger, W.F. Pickl, H. Esterbauer, C. Sillaber, H. Maeda, P. Valent, Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells, Blood, 110 (2007) 661-669. (Ph.D degree related) 73. A.K. Iyer, K. Greish, T. Seki, S. Okazaki, F. Fang, K. Takeshita, H. Maeda, Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation, J Drug Target, 15 (2007) 496-506. (Ph.D degree related) 74. A.K. Iyer, K. Greish, J. Fang, R. Murakami, H. Maeda, High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor, Biomaterials, 28 (2007) 1871-1881. 75. K. Greish, Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines, J Drug Target, 15 (2007) 457-464. (Ph.D degree related) 76. J. Daruwalla, K. Greish, M. Nikfarjam, I. Millar, C. Malcontenti-Wilson, A.K. Iyer, C. Christophi, Evaluation of the effect of SMA-pirarubicin micelles on colorectal cancer liver metastases and of hyperbaric oxygen in CBA mice, J Drug Target, 15 (2007) 487-495. 77. Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H., Exploiting the enhanced permeability and retention effect for tumor targeting. Drug discovery today 2006, 11 (17-18), 812-818. (Ph.D degree related) 78. K. Greish, I. Sanada, A.E.D. Saad, E. Hasanin, M. Kawasuji, F. Kawan, H. Maeda, Protective effect of melatonin on human peripheral blood hematopoeitic stem cells against doxorubicin cytotoxicity, Anticancer Res, 25 (2005) 4245-4248. (Ph.D degree related) 79. K. Greish, A. Nagamitsu, J. Fang, H. Maeda, Copoly(styrene-maleic acid) - Pirarubicin micelles: High tumor-targeting efficiency with little toxicity, BioconjugChem, 16 (2005) 230-236. (Ph.D degree related) 80. Fang, J., Greish, K., Maeda, H (2005). Focusing on the EPR-effect of polymer therapeutic and cancer therapy Pharm. Teck. Japan 21, 1981-1990. (In Japanese). (Ph.D degree related) 81. K. Greish, T. Sawa, J. Fang, T. Akaike, H. Maeda, SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours, Journal of Controlled Release, 97 (2004) 219-230. (Ph.D degree related) 82. J. Fang, T. Sawa, T. Akaike, K. Greish, H. Maeda, Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin, International Journal of Cancer, 109 (2004) 1-8. 83. Fang, J.; Sawa, T.; Akaike, T.; Akuta, T.; Sahoo, S. K.; Khaled, G.; Hamada, A.; Maeda, H., In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer research 2003,63 (13), 3567-74. 84. K. Greish, J. Fang, T. Inutsuka, A. Nagamitsu, H. Maeda, Macromolecular therapeutics - Advantages and prospects with special emphasis on solid tumour targeting, ClinPharmacokinet, 42 (2003) 1089-1105.(Ph.D degree related) 85. Ehab M., Sohair, E., Greish, K.,El Zawaway, M. (1998). Aggressive NHL: Prognostic factors and early results of treatment in Suez Canal University. Med. J. Univ. 22, 1-10 Peer reviewed books, book chapters, books edited 1. Alimoradi H, Matikonda S S, Gamble A B, Giles G I , Greish K. (2017) Redox activated polymeric nanoparticles in tumor therapy. Nanostructures for Drug Delivery. Elsevier (DOI: 10.1016/B978-0- 323-46143-6.00010-5 2. Jasim A, Abdelghany S, Greish K. (2016) Current Update on the Role of Enhanced Permeability and Retention Effect in Cancer Nanomedicine. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. Elsevier (in press) 3. Nehoff H, Parayath NN, Taurin S, Greish K. (2014) In Vivo Evaluation of Acute and Chronic Nanotoxicity. Handbook of Nanotoxicology, Nanomedicine and Stem Cell Use in Toxicology. 2014:65-86. 4. Sundararajan, V., Rosengren, R., Greish, K. (2014). Curcumin analogues for the treatment of breast cancer revisited: the nanotechnology approach. In: Curcumin: Synthesis, Emerging Role in Pain management and Health Implications. Nova Science Publishers, Inc. chapter 14 , page 347. 5. Nehoff, H., Taurin, S., Greish, K. (2013) Toxicological assessment of nanomedicine. In: Nanoparticulate Drug Delivery Systems: Strategies, Technologies, and Applications. PP. 279-303. 6. Taurin, S., Greish, K. (2013) Enhanced Vascular Permeability in Solid Tumors: A Promise for Anticancer Nanomedicine.In:Cancer Metastasis - Biology and Treatment. PP. 81-119. 7. Taurin, S., Nehoff, H., van Aswegen, T., Greish, K. (2013) Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots. In. Cancer Targeted Drug Delivery: Elusive Dream. PP. 207-240. 8. Greish, K. (2010) Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. In Cancer Nanotechnology, pp. 25-37, Humana Press 9. Maeda, H., Greish, K., Sawa, T., Fang, J. (2006) The EPR effect and polymeric drugs: Paradigm shift for cancer chemotherapy in the 21st century Adv. Polym. Sci. 193, 103-121. 10. Greish, K., Arun, I., Fang, J., Maeda, H. (2006) Enhanced permeability and retention (EPR) effect and tumor-selective delivery of anticancer drugs. In Delivery of Protein and Peptide Drugs in Cancer, ed, V, P Torchilin. Imperial Collage Press, London, 3752.

Refereed conference proceedings (selected from >150) A. Journal publication as a supplement resulting from meetings

1. H. Maeda, A. Nagamitsu, K. Greish, Treatments of Hepatoma and Other Abdominal Cancers Using Smancs/Lipiodol Given Intraarterially under Angiotensin-Ii Induced High Blood-Pressure, Journal of Hepatology, 54 (2011) S392-S392. 2. J. Daruwalla, K. Greish, C. Malcontenti-Wilson, V. Muralidharan, H. Maeda, C. Christophi, SMA- pirarubicin induces tumor selective oxidative damage and reduces tumor hypoxia, Annals of Oncology, 18 (2007) Vii34-Vii34. 3. M. Kneidinger, K.V. Gleixner, R. Kondo, P. Samorapoompichit, A. Vales, M.T. Krauth, M. Mayerhofer, A. Gruze, W.F. Pickl, K. Greish, A. Boehm, W.R. Sperr, H. Maeda, P. Valent, Heme oxygenase-1 (HO-1)/Heat shock protein 32 (Hsp32) as a novel survival factor and target in AML., Blood, 108 (2006) 539a-539a. 4. K.V. Gleixner, M. Matthias, A. Vales, A. Gruze, M. Kneidinger, G. Hoermann, M.T. Krauth, R. Kondo, K. Sonneck, P. Samorapoompichit, E. Lackner, K. Greish, W.F. Pickl, C. Sillaber, C.C. Zielinski, H. Maeda, P. Valent, Targeting of heat shock protein 32 (Hsp32) in neoplastic cells by styrene maleic acid zinc protoporphyrin (SMA-ZnPP) is associated with reduced growth and induction of apoptosis., Blood, 108 (2006) 159b-159b. 5. R. Kondo, M. Mayerhofer, K. Gleixner, A. Vales, M.T. Krauth, S. Derdak, A. Gruze, W. Pickl, C. Sillaber, K. Greish, H. Maeda, P. Valent, Heme oxygenase-1 (1HO-1): A novel KIT D816V- dependent target in neoplastic human mast cells (HMC-1), Blood, 106 (2005) 983a-983a. 6. M. Mayerhofer, K.J. Aichberger, S. Florian, M.T. Krauth, S. Derdak, H. Esterbauer, O. Wagner, W.F. Pickl, E. Selzer, M.W. Deininger, B.J. Druker, K. Greish, H. Maeda, C. Sillaber, P. Valent, The heme oxygenase-1-targeting compound PEG-ZnPP inhibits growth of imatinib-resistant BCR/A BL- transformed cells., Blood, 104 (2004) 548a-548a.

B. Refereed conference proceedings

1. Hayley Nehoff, Sebastien Taurin, Jasper Diong, Rhonda J. Rosengren and Khaled Greish, Synthesis and characterization of styrene maleic acid nanomicelles encapsulating the curcumin derivative RL71 for treatment of triple negative breast cancer. Queenstown Molecular biology meeting, 2012. 2. Sebastien Taurin, Jasper Diong, Hayley Nehoff, Lesley Larsen, Rhonda Rosengren, Khaled Greish, New drug delivery platform of a curcumin derivative for the treatment of estrogen receptor negative breast cancer. 71st annual meeting of the Japanese Cancer Association. P-1138, page 161. 3. Sebastien Taurin, Hayley Nehoff, Jasper Diong, Amol Shindikar, Lesley Larsen, Rhonda Rosengren, Khaled Greish.Synthesis of a curcumin derivative RL71 micelle for the treatment of triple negative breast cancer. Drug Delivery Australia, 6th annual meeting of the Australian chapter of the controlled release society, 2012. Page 150 4. Hayley Nehoff, Sebastien Taurin, Khaled Greish, Preparation, characterisation and initial in vitro cytotoxicity of Micellar Doxorubicin.. Drug Delivery Australia, 6th annual meeting of the Australian chapter of the controlled release society, 2012. Page 130 5. Greish, K.: EPR effect for targeted anticancer Nanomedicine, are we there yet?, 12th European Symposium on Controlled Drug Delivery, Egmondaan Zee, The Netherlands ,4-6 April 2012 6. Greish, K., Enhanced permeability and retention of nanomedicine in solid tumor, mission in progress, 14th conference on formulation and deliver of bioactive, Dunedin 16-17 February 2012 7. A. Gormley, A. Malugin, A. Ray, K. Greish, R. Robinson, J. Hui, and H. Ghandehari, Cellular Uptake and Biodistribution of Targeted and Non-Targeted Gold Nanorods for Photothermal Therapy of Prostate Tumors, Innovative Minds in Prostate Cancer Today (IMPaCT) Conference, Hilton Orlando, Florida, March 9-12, 2011. Conference Paper, Presented, 03/2012 8. Gormley, A. Malugin, A. Ray, K. Greish, R. Robinson J. Hui, and H. Ghandehari, Cellular Uptake and Biodistribution of Targeted and Non-Targeted Gold Nanorods for Photothermal Therapy, 8th International Nanomedicine and Drug Delivery Symposium, Omaha, Nebraska, October 3-5, 2010. Conference Paper, Presented, 10/2010. 9. K. Greish, A. Ray, H. Bauer, N. Larson, A. Malugin, D. Pike, and H. Ghandehari, Anticancer and Antiangiogenic Activity of HPMA Copolymer-Aminohexylgeldanamycin-RGDfK Conjugates for Prostate Cancer Therapy, 6th Annual Utah Statewide Nanotechnology Conference, Salt Lake City, Utah, October 14-15, 2010. Conference Paper, Presented, 10/2010 10. K. Greish, A. Ray, H. Bauer, N. Larson, A. Malugin, D. Pike, and H. Ghandehari, Anticancer and Antiangiogenic Activity of HPMA Copolymer-Aminohexylgeldanamycin-RGDfK Conjugates for Prostate Cancer Therapy, 8th International Nanomedicine and Drug Delivery Symposium, Omaha, Nebraska, October 3-5, 2010. Conference Paper, Presented, 10/2010. 11. G. Thiagarajan, K. Greish, R. Price, H. Bauer, A. Burckle, D. Hubbard, S. Sadekar, H. Herd, T. Yu, A. Anwar, and H. Ghandehari, Charge-Based In-Vivo Targeting and Toxicity of Dendritic Constructs, 6th Annual Utah Statewide Nanotechnology Conference, Salt Lake City, Utah, October 14-15, 2010. Conference Paper, Presented, 10/2010. 12. G. Thiagarajan, K. Greish, R. Price, H. Bauer, A. Burckle, D. Hubbard, S. Sadekar, H. Herd, T. Yu, A. Anwar, A. Ray, and H. Ghandehari, Charge-Based In-Vivo Targeting and Toxicity of Dendritic Constructs, 8th International Nanomedicine and Drug Delivery Symposium, Omaha, Nebraska, October 3-5, 2010. Conference Paper, Presented, 10/2010. 13. A. Gormley, R. Robinson, J. Hui, A. Malugin, A. Ray, K. Ray, K. Greish, and H. Ghandehari, Cellular Uptake and Biodistribution of Surface Functionalized Gold Nanorods for Photothermal Therapy, 6th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 10-11, 2010. Conference Paper, Presented, 09/2010. 14. J. Gustafson, R. Price, K. Greish, and H. Ghandehari, Safety of Matrix-Mediated Adenoviral Gene Delivery with Silk-Elastinlike Hydrogels, 6th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 10-11, 2010. Conference Paper, Presented, 09/2010. 15. A. Ray, N.K. Larson, D. B. Pike, H. Bauer, M. Gruner, A. Malugin, K. Greish, and H. Ghandehari, HPMA Copolymer-Docetaxel-RGDfK Conjugates for Prostate Cancer Therapy, 6th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 10-11, 2010. Conference Paper, Presented, 09/2010. 16. R. Price, J. Gustafson, K. Greish, J. Frandsen, and H. Ghandehari, Comparison of Recombinant Silk- Elastinlike Hydrogels for Viral Gene Delivery with Poloxamers, 6th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 10-11, 2010. Conference Paper, Presented, 09/2010. 17. K. Greish, G. Thiagarajan, H. Herd, R. Price, H. Bauer, T. Yu, A. Anwar, and H. Ghandehari, In Vivo Nanotoxicity of Dendritic and Silica Constructs, 6th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 10-11, 2010. Conference Paper, Presented, 09/2010. 18. K. Greish, H. Herd, G. Thiagarajan, R. Price, H. Bauer, T. Yu, A. Anwar, H. Ghandehari, In Vivo Evaluation of Nanomaterial Biosafety: Evidence of Disseminated Intravascular Coagulopathy (DIC) in Response to Cationic Dendrimer Administration, 37th Annual Meeting and Exposition of the Controlled Release Society, Portland, Oregon, July 10-14, 2010. Conference Paper, Presented, 07/2010. 19. A. Ray, K. Greish, D.B. Pike, N.K. Larson, M. Gruner, H. Ghandehari, HPMA Copolymer- Docetaxel-RGDfK Conjugates for Prostate Cancer Therapy, 37th Annual Meeting and Exposition of the Controlled Release Society, Portland, Oregon, July 10-14, 2010.. Conference Paper, Presented, 07/2010. 20. J. Gustafson, R. Price, K. Greish, and H. Ghandehari, Safety of Matrix-Mediated Adenoviral Gene Delivery with Silk-Elastinlike Hydrogels, 37th Annual Meeting and Exposition of the Controlled Release Society, Portland, Oregon, July 10-14, 2010. Conference Paper, Presented, 07/2010. 21. R. Price, K. Greish, J. Frandsen, J. Gustafson, and H. Ghandehari, Comparison of Recombinant Silk- Elastinlike Hydrogels for Viral Gene Delivery with Poloxamers, 37th Annual Meeting and Exposition of the Controlled Release Society, Portland, Oregon, July 10-14, 2010. Conference Paper, Presented, 07/2010. 22. J. Gustafson, K. Greish, J. Frandsen, S. Scharff, R. Price, and H. Ghandehari, Recombinant Silk- Elastinlike Polymers Localize Expression, Increase Efficacy, and Improve Safety of Virus-Mediated Gene Directed Enzyme-Prodrug Therapy, 8th International Conference and Workshop on Biological Barriers, Saarbrucken, , March 21-April 1, 2010. Conference Paper, Presented, 03/2010. 23. K. Greish, H. Herd, G. Thiagarajan, R. Price, T. Yu, H. Bauer, A. Anwar, H. Ghandehari, In Vivo Toxicity of Silica and Dendritic Nanoconstructs, Symposium on Biomedical Polymers for Drug Delivery, Salt Lake City, UT, March 26-27, 2010. Conference Paper, Presented, 03/2010. 24. H. Ghandehari, K. Greish, J. Gustafson, J. Frandsen, R. Price, Silk-Elastinlike Hydrogels for Cancer Gene Therapy, Symposium on Biomedical Polymers for Drug Delivery, Salt Lake City, UT, March 26- 27, 2010. Conference Paper, Presented, 03/2010. 25. A. Gustafson, K. Greish, J.C. Gifford, and H. Ghandehari, Silk-Elastinlike Polymers for Spatial and Temporal Control of Solid Tumor Gene Therapy, NanoUtah, 4th Annual Utah Statewide Nanotechnology Conference, Salt Lake City, Utah, October 16-17, 2008. Conference Paper, Presented, 10/16/2008. 26. A. Gustafson, K. Greish, J.C. Gifford, and H. Ghandehari, Silk-Elastinlike Polymers for Spatial and Temporal Control of Solid Tumor Gene Therapy, 4th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 5-6, 2008. Conference Paper, Presented, 09/05/2008. 27. A. Gustafson, K. Greish, J.C. Gifford, and H. Ghandehari, Silk-Elastinlike Polymers for Spatial and Temporal Control of Solid Tumor Gene Therapy, 4th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 5-6, 2008. Conference Paper, Presented, 09/05/2008. 28. A. Gustafson, K. Greish, J.C. Gifford, and H. Ghandehari, Silk-Elastinlike Polymers for Spatial and Temporal Control of Solid Tumor Gene Therapy, 4th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 5-6, 2008. Conference Paper, Presented, 09/05/2008. 29. A. Gustafson, K. Greish, J.C. Gifford, and H. Ghandehari, Silk-Elastinlike Polymers for Spatial and Temporal Control of Solid Tumor Gene Therapy, 4th Annual Mountain West Biomedical Engineering Conference, Park City, Utah, September 5-6, 2008. Conference Paper, Presented, 09/05/2008. 30. Greish, K.,Iyer,K., Fang, J., Maeda, H., Targeted Delivery of Polymeric SMA-Aclarubicin Micelles for Reversing Anti-Cancer Drug Resistance. 34th Annual Meeting & Exposition of the Controlled Release Society (CRS), Long Beach, California, USA, July 7-11, 2007. 31. E. Hadzijusufovic, L. Rebuzzi, K.V. Gleixner, A. Vales, R. Kondo, A. Gruze, M. Kneidinger, M.T. Krauth, P. Samorapoompichit, K. Greish, M. Mayerhofer, W.F. Pickl, H. Maeda, M. Willmann, P. Valent, Abstracts presented at the ESVONC Autumn Meeting, Budapest, Hungary, 13-15 September 2007, Veterinary and Comparative Oncology, 6 (2008) 84-94. 32. Greish, K.,Iyer,K., Fang, J., Maeda, H.,. Copoly(styrene-maleic acid)(SMA) micelles: polymeric nanocarrier for versatile targeted anticancer drug delivery based on EPR-effect. Drug, Drug Delivery System, 21-3, 330, Kumamoto, Japan May,2006. 33. Greish, K.,Kawasuji, M., and Maeda, H., Protective effect of melatonin on human peripheral blood cells hematopoietic stem cells against doxorubicin cytotoxicty. 64th Annual Meeting of the Japanese Cancer Association, Yokohama, Japan, September, 2006. 34. Greish, K.,Iyer,K., Fang, J., Maeda, H., SMA- pirarubicin micelles, a selective anticancer targeted drug with high efficacy and little toxicity due to EPR-effect, Presented at the 21st Annual Meeting of the Biohybrid Society of Japan, Yokohama, Japan, November, 2006. 35. Greish, K.,Iyer, K., Fang,J., Maeda,H., Highly improved plasma concentration and tumor distribution of SMApirarubicin micelles based on EPR-effect, Presented at 33rd Annual Meeting & Exposition of the Controlled Release Society (CRS) at Vienna, Austria, July, 2006. 36. Greish, K.,Iyer, K., Kawasuji,M., Maeda,H., Pharmacokinetics and tissue distribution of SMA-THP, A further demonstration of the EPR –effect, Drug Delivery System, 300 , 20-3 May, 2005. 37. Greish, K.,Nikfarjam, M, Christophi, C.,Maeda,H.,, Evaluation of Antimetastatic Effect of SMA- Pirarubicin Micelles in Mice, 63th Annual meeting of the Japanese Cancer Association, Fukoka, 2004.

Patents 1. US patent 7,682,630 (2009) Antitumor agent and process for producing the same. Same patent approved as WO patent 2,004,103,409, CA patent , CA 2,605,205 , and EP patent 1,627,645 2. US Patent 8,128,959B2 (2012) Polymeric pharmaceutical agent for treatment of cancer and method for production of the same. 3. US Patent Application 20,150,152,165(2015) Matrix metalloproteinase cleavable protein polymers for cancer gene therapy. Funding Research Grants (significant grants only)

(1) Principal investigator or Co-Principle investigator

I. AGU/RCSI (2016-2018) AGURSCI-2016-1 II. “Selective targeting of breast cancer cells by new Duocarmycin derivatives using Nanotechnology” III. PI Ibrahim El-Deeb, Khaled Greish, and Moiz Bakhiet.

IV. AGU/RCSI (2017-2019) AGURSCI-2017-2 V. “Using Nanotechnology for selective targeting of new Curcumin derivatives for treatment of breast cancer “ VI. PI Khaled Greish, Fiza Rashid and Salem Frederick

VII. Arabian Gulf university grant (2016-2017)

VIII. The use of Synthetic Cannabinoid analogue WIN55, 212-2 Nano- micelles as novel treatment for cancer

2015:

Genesis oncology Grants; 70,000 $NZ. “Targeted delivery of raloxifene nanomedicine as a treatment for castrate resistant prostate cancer” .1/1/2015-31/12/2016. PI Sebastien Taurin, Co-I Khaled Greish. New Zealand Breast Cancer Foundation, 200,000 $NZ. Phase II “Development of a novel nanomedicine for the treatment of triple negative breast cancer”, 1/8/2015-1/8/2016. PI Rhonda Rosengren, CO-I’s Khaled Greish, Sebastien Taurin.

2014:

I. University of Otago Research Grants (UORG), 30,265 $NZ. “The efficiency of styrene maleic acid (SMA) for oral delivery of anticancer Nanomedicine”, 1/1/2014- 31/12/2015. PI Khaled Greish, Co-I Sebastien Taurin.

II. Otago Medical Research Foundation, 19,882 $NZ. “Dual Nano- Miceller System for Enhanced Delivery of Chemotherapeutics to Resistant Pancreatic Cancer”, 01/04/2014- 31/03/2014. PI Khaled Greish , CO-I. Greg Giles

2013:

I. Otago School of Medical Sciences "Deans Bequest", 19,800 NZ $. “Development of Oral anticancer Nanomedicine using Styrene maleic acid (SMA) Doxorubicin Nanomicelles”, 1/7/2012-1/1/7013. PI Khaled Greish II. University of Otago Research Grants (UORG), 28,293 NZ $. “Development of folic acid targeted anticancer Nanomicelles for treatment of aggressive brain tumours", 1/1/2013-/1/1/2014. PI Khaled Greish, Co-I Sebastien Taurin. III. New Zealand Breast Cancer Foundation, 100,000 $NZ. “Development of a novel nanomedicine for the treatment of triple negative breast cancer”, 1/8/2013-1/8/2015. PI Rhonda Rosengren, CO-I’s Khaled Greish, Sebastien Taurin. IV. Otago Medical Research Foundation, 33,881 $NZ. “Encapsulation of raloxifene into styrene maleic acid micelles for the treatment of hormone refractory prostate cancer”, 01/07/2013- 30/06/2014. PI Sebastien Taurin, CO-I Khaled Greish. V. University of Otago Research Grants (UORG), 39,280 NZ $. “SMA-RL71 a new nanomedicine for the treatment of aggressive breast and prostate cancer”, 1/1/2013- /1/1/2014. Investigators: P I Rhonda Rosengren, CO-I’s : Helen Nicholson , and Khaled Greish VI. Maurice and Phyllis Paykel Trust, $5,000 NZ $. “SMA-RL71, a novel nanomedicine to halt metastasis of triple negative breast cancer”, 1.1.13-2031.12.2014. PI Rhonda Rosengren Co-I Khaled Greish. 2012:

I. Otago Medical Research Foundation (Laurenson Awards),“Nanomicelles of curcumin derivatives for the management of estrogen receptor negative breast cancer” 18,018 NZ $, ”, 1/1/2012-1/1/2013. PI Khaled Greish, Co-I Rhonda Rosengren. II. Otago School of Medical Science Strategic Research, ‘Nanomicelles of curcumin derivatives for the management of estrogen receptor negative breast cancer” 20,000 NZ $.” 1/1/2012-1/1/2013. PI Khaled Greish III. University of Otago Research Grants (UORG), 20,146 NZ $. “Cannabinoid nanoparticles for the treatment of neuropathic pain Investigators”, 1/1/2012-1/1/2013. PI John Ashton,, Co-I Khaled Greish External travel grants:

 2013:$1,300 Genesis Oncology Trust Professional Development Award. Award given to support attending the 38th Controlled Release Society annual meeting, Hawaii, USA.  2013, $4,000, Nano institute of Utah, and Department of Bioengineering, Utah university. Travel support to deliver invited lectures for the post-graduate BIOEN 6302 course.  2012: $2,533 - Genesis Oncology Trust Professional Development Award. Award given to support symposium invitation from the Controlled Release Society: 37 annual meeting. Quebec, Canada  2012: $ 600 Controlled Release Society, Award given to support symposium invitation from the Controlled Release Society: 37 annual meeting. Quebec, Canada  2012: $ 1500, Maurice and Phyllis Paykel Trust Travel Grant. Award given to support symposium invitation from the Controlled Release Society: 37 annual meeting. Quebec, Canada  2012: 50,000 Japanese Yen, travel award, Japanese Cancer Association. Award given to support symposium invitation from the Japanese Cancer Association71st annual meeting.

(d) Supervision of Postgraduate Students

Total Number 14, 10 are listed:

1. Stephanie Scharff ; MSc 2. Oliver Linsell ; MSc 3. Thalita Van Aswegen; MSc 4. Vignesh Sundararajan;MSc 5. Philipp Muller; MSc 6. Christel Hoeve; MSc 7. Neha Parayath; Ph.D. 8. Hayley Nehoff; Ph.D. 9. Houman AliMoradi; Ph.D 10. Fatma Bahman; Ph.D. 11. Maha Al Ghamdi

Professional Committees:

Chair, Research and Ethics committee

Chair, Animal facility Committee

Library Committee

Molecular Medicine PhD Committee

Master of Personalized Medicine Committee

Graduate study committee

CMMS research plan committee

Intellectual properties committee